Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | PYGL | P06737 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8427548 | 0.81 | CCR5 (0.32) | PYGL | |
| SCHEMBL8426360 | 0.81 | CCR5 (0.32) | PYGL | |
| SCHEMBL3282412 | 0.78 | — | — | |
| SCHEMBL9463026 | 0.74 | L3MBTL1 (0.47) | DPP4PIK3CD | |
| SCHEMBL7980484 | 0.74 | PYGL (0.33) | PYGL | |
| SCHEMBL8427917 | 0.73 | HSD11B1 (0.40) | DRD4 | |
| SCHEMBL8426947 | 0.73 | HSD11B1 (0.40) | DRD4 | |
| SCHEMBL658992 | 0.72 | L3MBTL1 (0.50) | PIK3CD | |
| SCHEMBL7994564 | 0.72 | L3MBTL1 (0.33) | — | |
| SCHEMBL21011622 | 0.71 | CCR5 (0.35) | DPP4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446114-B2 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | DPP4 310/4885PIK3CD 741/4885DRD4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.